Abstracts And Publications | A2 Biotherapeutics

Logic‑gated, allogeneic Tmod chimeric antigen receptor T‑cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI‑1 trial.

Kirtane K, Park JC, Ulrickson M, et al.

Poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. June 2025.

EVEREST‑2: Initial data of the logic‑gated Tmod chimeric antigen receptor T‑cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).

Punekar SR, Ward JP, Park JC, et al.

Poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. June 2025.

**A seamless phase 1/2 study of A2B694, a logic‑gated Tmod CAR T-cell therapy, in patients with mesothelin‑expressing solid tumors and human leukocyte antigen–A*02 loss of heterozygosity**

Molina J, Hazim A, Dorigo O, et al.

Poster presentation at the 2025 AACR Annual Meeting. April 2025.

Functional Screen to optimize logic gate potency and selectivity

Martire S, Gill T, McElvain M, et al.

Poster presentation at the 2025 AACR Annual Meeting. April 2025.

A logic-gated CAR T for post-transplant acute myeloid leukemia that distinguishes donor and recipient hematopoiesis

D. Manry, B. Luna, A. Winters, et al.

Poster presentation at the 2025 AACR Annual Meeting. April 2025.

Signal 1 boosters for Tmod: addressing the next obstactle in cell therapy for solid tumors

Manry D, K, Partin A, et al.

Poster presentation at the 2025 AACR Annual Meeting. April 2025.

Cytokine response and heme cell depletion and recovery after treatment with Tmod logic-gated chimeric antigen receptor T cells (CAR Ts) in patients with solid tumors

Hecht JR, Sattva N, Locke F, et al.

Poster presentation at the 2025 SITC Spring Scientific, Cellular Therapy for Solid Tumors, March 2025.

Recommendations for Defining Chimeric Antigen Receptor T‑Cell (CAR T) Dose‑Limiting Toxicities (DLTs) for Future Early‑Stage CAR T Therapy Studies

Locke F, Nikiforow S, Frigault M, et al.

Poster presentation at the 2025 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, February 2025.

Correlation of Mesothelin (MSLN) expression measured by RNA sequencing (RNAseq) and immunohistochemistry (IHC) in MSLN‑expressing tumors

Hecht JR, Grierson PM, Welling TH, et al.

Poster presentation at the 2025 ASCO Gastrointestinal Cancers Symposium, January 2025.

EVEREST‑2: A seamless phase 1/2 study of A2B694, a logic‑gated Tmod chimeric antigen receptor T‑cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)‑expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH)

Spencer K, Punekar S, Grierson PM, et al.

Poster presentation at the 2025 ASCO Gastrointestinal Cancers Symposium, January 2025.

Functional screen to optimize logic gate potency and selectivity

Martire S, Suryawwanshi V, Wang X, et al.

Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

Onboard, membrane-tethered IL-12 boosts potency and maintains selectivity of a Tmod NOT gate

Imboden S, Lee R, Zampieri A., et al.

Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

BASECAMP‑1 is an efficient pre‑screening study that identifies patients with HLA LOH and provides mutational, RNA‑Seq, and microbiome data for precision logic‑gated CAR T therapeutic trials

Molina J, Simeone D, Spencer K, et al.

Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

EVEREST‑1: Initial safety data from a seamless phase 1/2 study of A2B530, a logic‑gated Tmod CAR T‑cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA‑LOH

Grierson P, Punekar S, Hazim A, et al.

Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

Signal 1 boosters for Tmod: addressing the next obstacle in cell therapy for solid tumors

K, Oh J, Kirsh C, et al.

Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

Improving ethnic and racial diversity in biomarker-driven clinical trials: a proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A02 (HLA-A02) loss of heterozygosity (LOH)

Smith CJ, Simeone DM, Grierson PM, et al.

Poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. June 2024.

EVEREST‑2: A seamless phase 1 / 2 study of A2B694, a logic‑gated Tmod CAR T‑cell therapy, in patients with mesothelin‑expressing solid tumors with human leukocyte antigen‑A*02 loss of heterozygosity

Molina J, Hazim, A, Dorigo O, et al.

Poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2024.

EVEREST‑1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic‑gated Tmod CAR T‑cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)‑A*02 loss of heterozygosity (LOH)

Molina JR, Simeone DM, Smith CJ, et al.

Poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. June 2024.

EVEREST‑2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic‑gated Tmod CAR T‑cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)‑A*02 loss of heterozygosity (LOH)

Punekar SR, Hecht JR, Smith CJ, et al.

Poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. June 2024.

Defining The Biophysical Design Parameters For Logic-Gated CAR-T Systems

Partin AC, Bruno R, Shafaattalab S, et al.

Poster presentation for the 2024 PEGS Conference. May 2024.

BASECAMP‑1: A Master Prescreening Study to Identify Patients with High‑risk or Metastatic Solid Tumors with HLA Loss of Heterozygosity in Preparation for Tmod™ CAR T‑cell Therapy Trials

Simeone DM, Hecht JR, Smith C, et al.

Poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2023.

EVEREST-1: A Seamless Phase 1/2 Study of CEA-directed Logic-gated Tmod™ CAR T-cell Therapy (A2B530) in Adults with Solid Tumors Associated with CEA Expression Also Exhibiting HLA Loss of Heterozygosity (LOH)

Punekar SR, Welling T, Hecht JR, et al.

Poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting. November 2023.

BASECAMP-1: Leveraging Human Leukocyte Antigen A (HLA-A) Loss of Heterozygosity (LOH) in Solid Tumors to Identify Patients for Carcinoembryonic Antigen (CEA) and Mesothelin (MSLN) Logic-Gated Tmod Chimeric Antigen Receptor (CAR) T-Cell Therapy

Smith CJ, Lau S, Garon E, et al.

Poster presentation at the International Association for the Study of Lung Cancer (IASLC) 2023 Targeted Therapies of Lung Cancer Meeting. February 2023.

BASECAMP-1: Leveraging HLA-A Loss of Heterozygosity in Solid Tumors by NGS to Identify Patients with Relapsed Solid Tumors for Future CEA and MSLN Logic-gated Tmod CAR T-cell Therapy.

Simeone DM, Morelli MP, Hecht JR, et al.

Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

An NGS Assay to Identify HLA-A Loss of Heterozygosity for Future CEA and MSLN Logic-gated CAR-T Solid Tumor Protocols Designed for Reduced On-target, Off-tumor Toxicity

Kopetz S, Morelli MP, Molina J, et al.

Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

**A2B530, An Autologous CEA-directed Tmod T-cell therapy with An Inhibitory Receptor Gated by HLA-A*02 to Target Colorectal, Pancreatic, and Lung Cancer**

Hecht JR, Sandberg ML, Wang X, et al.

Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

A2B694, An Autologous Logic-gated Cell Therapy Targeting Mesothelin

Molina J, Tokatlian T, Wang J, et al.

Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

A Powerful, Precise Targeting System Controlled by Tumor Deletions Transforms CEA and MSLN CAR-T Cells Into Tumor-Selective Agents

Hamburger A, Xu H, Ando Y, et al.

Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T Cell Therapy

Molina J, Go W, Kopetz S, et al.

Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics

Warshaviak D, Nampe D, Wang X, et al.

Poster presentation at The Essential Protein Engineering & Cell Therapy Summit Virtual. August 2020.

Our Science

Posters

Logic‑gated, allogeneic Tmod chimeric antigen receptor T‑cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI‑1 trial.

EVEREST‑2: Initial data of the logic‑gated Tmod chimeric antigen receptor T‑cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).

**A seamless phase 1/2 study of A2B694, a logic‑gated Tmod CAR T-cell therapy, in patients with mesothelin‑expressing solid tumors and human leukocyte antigen–A*02 loss of heterozygosity**

Functional Screen to optimize logic gate potency and selectivity

A logic-gated CAR T for post-transplant acute myeloid leukemia that distinguishes donor and recipient hematopoiesis

Signal 1 boosters for Tmod: addressing the next obstactle in cell therapy for solid tumors

Cytokine response and heme cell depletion and recovery after treatment with Tmod logic-gated chimeric antigen receptor T cells (CAR Ts) in patients with solid tumors

Recommendations for Defining Chimeric Antigen Receptor T‑Cell (CAR T) Dose‑Limiting Toxicities (DLTs) for Future Early‑Stage CAR T Therapy Studies

Correlation of Mesothelin (MSLN) expression measured by RNA sequencing (RNAseq) and immunohistochemistry (IHC) in MSLN‑expressing tumors

EVEREST‑2: A seamless phase 1/2 study of A2B694, a logic‑gated Tmod chimeric antigen receptor T‑cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)‑expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH)

Functional screen to optimize logic gate potency and selectivity

Onboard, membrane-tethered IL-12 boosts potency and maintains selectivity of a Tmod NOT gate

BASECAMP‑1 is an efficient pre‑screening study that identifies patients with HLA LOH and provides mutational, RNA‑Seq, and microbiome data for precision logic‑gated CAR T therapeutic trials

EVEREST‑1: Initial safety data from a seamless phase 1/2 study of A2B530, a logic‑gated Tmod CAR T‑cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA‑LOH

Signal 1 boosters for Tmod: addressing the next obstacle in cell therapy for solid tumors

Improving ethnic and racial diversity in biomarker-driven clinical trials: a proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A02 (HLA-A02) loss of heterozygosity (LOH)

EVEREST‑2: A seamless phase 1 / 2 study of A2B694, a logic‑gated Tmod CAR T‑cell therapy, in patients with mesothelin‑expressing solid tumors with human leukocyte antigen‑A*02 loss of heterozygosity

EVEREST‑1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic‑gated Tmod CAR T‑cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)‑A*02 loss of heterozygosity (LOH)

EVEREST‑2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic‑gated Tmod CAR T‑cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)‑A*02 loss of heterozygosity (LOH)

Defining The Biophysical Design Parameters For Logic-Gated CAR-T Systems

BASECAMP‑1: A Master Prescreening Study to Identify Patients with High‑risk or Metastatic Solid Tumors with HLA Loss of Heterozygosity in Preparation for Tmod™ CAR T‑cell Therapy Trials

EVEREST-1: A Seamless Phase 1/2 Study of CEA-directed Logic-gated Tmod™ CAR T-cell Therapy (A2B530) in Adults with Solid Tumors Associated with CEA Expression Also Exhibiting HLA Loss of Heterozygosity (LOH)

BASECAMP-1: Leveraging Human Leukocyte Antigen A (HLA-A) Loss of Heterozygosity (LOH) in Solid Tumors to Identify Patients for Carcinoembryonic Antigen (CEA) and Mesothelin (MSLN) Logic-Gated Tmod Chimeric Antigen Receptor (CAR) T-Cell Therapy

BASECAMP-1: Leveraging HLA-A Loss of Heterozygosity in Solid Tumors by NGS to Identify Patients with Relapsed Solid Tumors for Future CEA and MSLN Logic-gated Tmod CAR T-cell Therapy.

An NGS Assay to Identify HLA-A Loss of Heterozygosity for Future CEA and MSLN Logic-gated CAR-T Solid Tumor Protocols Designed for Reduced On-target, Off-tumor Toxicity

**A2B530, An Autologous CEA-directed Tmod T-cell therapy with An Inhibitory Receptor Gated by HLA-A*02 to Target Colorectal, Pancreatic, and Lung Cancer**

A2B694, An Autologous Logic-gated Cell Therapy Targeting Mesothelin

A Powerful, Precise Targeting System Controlled by Tumor Deletions Transforms CEA and MSLN CAR-T Cells Into Tumor-Selective Agents

BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T Cell Therapy

A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics